Xilio Therapeutics (XLO) analyst forecast and price target
Analyst forecast
Consensus of 1 analyst rating
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Leerink Partners | Initiated Coverage | Outperform | $2.00 | Aug 6, 2025 |
| Raymond James | Maintained | Outperform | $4.00 from $6.00 | Nov 8, 2024 |
| Chardan Capital | Maintained | Buy | $7.00 | May 30, 2023 |
| Chardan Capital | Maintained | Buy | $7.00 | May 11, 2023 |
Frequently asked questions
Is XLO a buy, sell, or hold?
Analysts covering Xilio Therapeutics currently average a Buy rating: 1 buy, 0 hold and 0 sell, from 1 analyst. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on XLO?
On Aug 6, 2025, Leerink Partners initiated coverage of Xilio Therapeutics at Outperform with a price target of $2.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.